The evolution of lung cancer and impact of subclonal selection in TRACERx
The Francis Crick Institute · Cancer Research UK · +67 more institutions
Abstract
. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer genes were under significant subclonal selection, including classical tumour initiators such as TP53 and KRAS. We defined evolutionary dependencies between drivers, mutational processes and whole genome doubling (WGD) events. Despite patients having a history of smoking, 8% of lung…
Citation impact
- FWCI
- 75.62
- Percentile
- 100%
- References
- 94
Authors
287- AMAlexander M. FrankellCorresponding
The Francis Crick Institute, Cancer Research UK, London Cancer, CRUK Lung Cancer Centre of Excellence, University College London
- MDMichelle Dietzen
The Francis Crick Institute, Cancer Research UK, London Cancer, CRUK Lung Cancer Centre of Excellence, University College London
- MAMaise Al Bakir
The Francis Crick Institute, Cancer Research UK, London Cancer, CRUK Lung Cancer Centre of Excellence, University College London
- ELEmilia L. Lim
Guy's and St Thomas' NHS Foundation Trust, The Francis Crick Institute, Cancer Research UK, Harefield Hospital, London Cancer, CRUK Lung Cancer Centre of Excellence, University College London, Imperial College London
- TKTakahiro Karasaki
The Francis Crick Institute, Cancer Research UK, London Cancer, CRUK Lung Cancer Centre of Excellence, University College London
Topics & keywords
- Selection (genetic algorithm)
- Cancer
- Lung cancer
- Biology
- Medicine
- Oncology
- Genetics
- Computer science
- Good health and well-being
Funding
- AAAmerican Association for Cancer Research
- BCBreast Cancer Research Foundation
- LFLUNGevity Foundation
- CPCancer Prevention and Research Institute of TexasAward: RR210006
- IAInternational Association for the Study of Lung Cancer
- EIEntertainment Industry Foundation
- LCLung Cancer Research Foundation
- AUAarhus Universitet
- RCRoy Castle Lung Cancer FoundationAward: MR/T02481X/1
- WTWellcome TrustAwards: CC2041, 211179/Z/18/Z
- FCFrancis Crick InstituteAward: CC2041
- MFMark Foundation For Cancer ResearchAward: 21-029-ASP
- CRCancer Research UKAwards: A27412, C7893/A26233, RCCCDF-Nov21\100005, C36463/A22246, C11496/A30025, A22246, C416/A21999, A17786, C36463/A20764, CC2008, C36463, C416/, A20764, CANTAC721\100022, ID16584, EDDCPGM\100002, C444/A15953, 100002, C11496/A17786, CC2041, CTRQQR-2021\100010
- NINational Institute for Health and Care ResearchAward: C444/A15953
- RSRoyal SocietyAwards: RSRP\R\210001, 211179/Z/18/Z, 211179, RP/EA/180007
- FFFoulkes Foundation
- UCUniversity College LondonAwards: C36463/A20764, C36463/A22246, MR/T02481X/1, UCL/12/0279
- ECEuropean CommissionAwards: FP7-PEOPLE-2013, 607722, 835297
- RTRosetrees TrustAwards: MR/T02481X/1, ID16584
- AUAarhus Universitets ForskningsfondAward: AUFF-E-2018-7-14
- LLundbeckfondenAward: R272-2017-4040
- NNNovo Nordisk
- UCUniversity College London Hospitals NHS Foundation Trust
- NNNovo Nordisk FondenAwards: 16584, ID 16584, ID16584, NNF21OC0071483
- HLH. Lundbeck A/S
- URUK Regenerative Medicine Platform
- CLCRUK Lung Cancer Centre of ExcellenceAward: C11496/A30025
- SUStand Up To CancerAwards: SU2C-AACR-DT23-17, AACR-DT23-17
- MBManchester Biomedical Research CentreAward: MR/T02481X/1
- IEImperial Experimental Cancer Medicine Centre
- MRMedical Research CouncilAwards: MR/T02481X/1, CC2008, MR/W025051/1, MR/V033077/1, MR/T02481X/1, MR/W025051/1, CC2041
- JSJapan Society for the Promotion of ScienceAward: 2018-7
- FPFP7 People: Marie-Curie ActionsAwards: 607722, FP7-PEOPLE-2013